Morgan D O, Roth R A
Biochem Biophys Res Commun. 1986 Aug 14;138(3):1341-7. doi: 10.1016/s0006-291x(86)80430-2.
A monoclonal antibody was identified which equally inhibits 125I-labeled insulin and insulin-like growth factor I (IGF-I) binding to their respective receptors in human IM-9 lymphoid cells and solubilized placenta receptor preparations. In contrast, this monoclonal antibody inhibits insulin but not IGF-I binding to human hepatoma (HepG2) cells, fibroblasts and muscle cells. These results indicate that there are two distinct species of the type I insulin-like growth factor receptor (which we have named type IA and type IB) and suggest that this monoclonal antibody may be useful in determining whether different biological effects are mediated through these two receptors.
一种单克隆抗体被鉴定出来,它能同等程度地抑制125I标记的胰岛素和胰岛素样生长因子I(IGF-I)与它们在人IM-9淋巴细胞和溶解的胎盘受体制剂中各自受体的结合。相比之下,这种单克隆抗体抑制胰岛素与人类肝癌(HepG2)细胞、成纤维细胞和肌肉细胞的结合,但不抑制IGF-I的结合。这些结果表明存在两种不同类型的I型胰岛素样生长因子受体(我们将其命名为IA型和IB型),并表明这种单克隆抗体可能有助于确定不同的生物学效应是否通过这两种受体介导。